Q 
Qiagen QGEN · USD
Health Care · Life Sciences Tools & Services · US listing · 🇺🇸 United States
DAX
50.55
+0.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$2.09bn
FY2016FY2025
Net income
$424.9m
FY2016FY2025
Free cash flow
$453.3m
FY2016FY2025
Shareholders' equity
$3.78bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.09bn | $1.98bn | $1.97bn | $2.14bn | $2.25bn | $1.87bn | $1.53bn | $1.50bn | $1.42bn | $1.34bn |
| Gross profit | $1.29bn | $967.4m | $1.23bn | $1.38bn | $1.45bn | $1.23bn | $1.01bn | $1.00bn | $922.6m | $844.7m |
| Research and development | $187.5m | $193.5m | $198.5m | $189.9m | $190.0m | $149.1m | $157.4m | $161.9m | $154.1m | $176.1m |
| Operating income | $520.3m | $97.7m | $409.9m | $531.5m | $630.1m | $447.7m | −$25.7m | $266.6m | $153.4m | $98.8m |
| Net income | $424.9m | $83.6m | $341.3m | $423.2m | $512.6m | $359.2m | −$41.5m | $190.4m | $40.4m | $80.4m |
| Diluted earnings per share | 2.05 | 0.38 | 1.52 | 1.89 | 2.21 | 1.53 | -0.18 | 0.82 | 0.17 | 0.35 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.30bn | $5.69bn | $6.12bn | $6.29bn | $6.15bn | $5.87bn | $5.24bn | $5.75bn | $5.04bn | $4.31bn |
| Cash and short-term investments | $1.10bn | $1.15bn | $1.06bn | $1.42bn | $1.07bn | $715.2m | $753.2m | $1.42bn | $1.02bn | $532.2m |
| Total liabilities | $2.52bn | $2.12bn | $2.31bn | $2.82bn | $3.05bn | $3.07bn | $2.70bn | $3.11bn | $2.50bn | $1.70bn |
| Debt | $1.65bn | $1.39bn | $1.51bn | $1.86bn | $1.94bn | $1.92bn | $1.71bn | $2.17bn | $1.76bn | $1.07bn |
| Shareholders' equity | $3.78bn | $3.57bn | $3.81bn | $3.47bn | $3.10bn | $2.80bn | $2.54bn | $2.63bn | $2.54bn | $2.61bn |
| Shares outstanding | 208m | 218m | 224m | 223m | 232m | 235m | 231m | 232m | 232m | 231m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $654.3m | $673.6m | $459.5m | $715.3m | $639.0m | $492.3m | $330.8m | $359.5m | $286.8m | $341.6m |
| Capital spending | −$201.0m | −$167.2m | −$162.8m | −$149.3m | −$206.5m | −$304.2m | −$274.9m | −$150.8m | −$124.4m | −$93.9m |
| Free cash flow | $453.3m | $506.4m | $296.7m | $565.9m | $432.5m | $188.0m | $56.0m | $208.7m | $162.4m | $247.7m |
| Dividends paid | −$54.2m | — | — | −$25.4m | — | −$622.2m | — | −$567.3m | −$769.7m | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $535.0m | $492.3m | $540.4m | $532.6m | $533.5m | $483.5m | $521.2m | $501.9m |
| Gross profit | $338.0m | $309.6m | $317.3m | $331.3m | $334.3m | $308.7m | $333.3m | $308.3m |
| Operating income | $140.8m | $96.9m | $153.9m | $129.2m | $121.9m | $115.3m | $119.1m | $112.1m |
| Net income | $103.4m | $68.0m | $107.8m | $130.0m | $96.3m | $90.8m | $88.3m | $98.1m |
| Diluted earnings per share | 0.50 | 0.33 | 0.52 | 0.63 | 0.46 | 0.44 | 0.41 | 0.45 |
| Cash from operations | $200.0m | $100.0m | $188.0m | $165.0m | $161.0m | $139.0m | $191.0m | $182.0m |
| Capital spending | −$42.0m | −$46.0m | −$70.0m | −$46.0m | −$40.0m | −$43.0m | −$49.0m | −$44.0m |
| Free cash flow | $158.0m | $54.0m | $118.0m | $119.0m | $121.0m | $96.0m | $142.0m | $138.0m |
| Total assets | $5.89bn | $5.78bn | $6.30bn | $6.55bn | $5.82bn | $5.55bn | $5.69bn | $6.27bn |
| Cash and short-term investments | $793.5m | $646.3m | $1.10bn | $1.69bn | $953.8m | $963.4m | $1.15bn | $1.48bn |
| Debt | $1.64bn | $1.65bn | $1.65bn | $2.13bn | $1.44bn | $1.41bn | $1.42bn | $1.92bn |
| Shareholders' equity | $3.36bn | $3.33bn | $3.78bn | $3.65bn | $3.51bn | $3.41bn | $3.57bn | $3.53bn |
Financial ratios
Data as of 8 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 61.8% | 48.9% | 62.8% | 64.7% | 64.4% | 65.9% |
| Operating margin | 25.0% | 8.3% | 24.6% | 26.7% | 30.2% | 27.3% |
| Net margin | 20.3% | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% |
| Return on equity | 11.2% | 2.3% | 9.0% | 12.2% | 16.6% | 12.8% |
| Return on assets | 6.7% | 1.5% | 5.6% | 6.7% | 8.3% | 6.1% |
| Free cash flow yield | 9.2% | 8.6% | 6.2% | 8.6% | 8.1% | 7.6% |
| Revenue growth | 5.7% | 0.7% | -8.2% | -4.9% | 20.4% | 22.5% |
| Earnings growth | 408.3% | -75.5% | -19.4% | -17.4% | 42.7% | -966.5% |
| Current ratio | 3.90x | 3.61x | 1.99x | 2.46x | 1.39x | 2.84x |
| Debt to equity | 0.44x | 0.40x | 0.40x | 0.54x | 0.63x | 0.70x |
| Equity ratio | 60.0% | 62.7% | 62.3% | 55.1% | 50.4% | 47.7% |
| Interest coverage | 15.74x | 3.76x | 9.05x | 9.78x | 12.49x | 7.16x |
| R&D as a share of sales | 9.0% | 9.8% | 10.1% | 8.9% | 8.4% | 8.0% |
| Buybacks as a share of market value | 4.7% | 2.6% | -0.2% | 3.6% | 1.3% | -1.5% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -0.8% | 2.2% | 5.0% |
| Operating income | -0.7% | 3.1% | 11.2% |
| Net income | 0.1% | 3.4% | 12.6% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 55.5% | 59.7% | 61.5% | 62.8% |
| Operating margin | 15.2% | 19.1% | 21.4% | 17.1% |
| Net margin | 12.5% | 15.6% | 17.4% | 13.1% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 22.0 | 116.1 | 29.4 | 27.1 | 25.9 | 35.6 | -194.5 | 43.4 | 182.9 | 86.1 |
| Price to sales | 4.5 | 4.9 | 5.1 | 5.4 | 5.9 | 6.8 | 5.3 | 5.5 | 5.2 | 5.2 |
Market value over time
30 Nov 2016 to 7 Oct 2026, in USD
$6.79bn$9.31bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 2% | -1% | -12% | -12% | 5% | 29% | 24% | 4% | 12% | 3% |
Dividends and splits
Per share, in the currency the company pays
Paid for 2 years. Last went ex-dividend on 2 Jul 2025.
| FY2025 | FY2024 | FY2017 | |
|---|---|---|---|
| Paid in the year | 0.25 | 1.357 | 1.154 |
- 20-to-19 reverse split · 8 Jan 2026
- 36-to-35 reverse split · 29 Jan 2025
- 25-to-24.25 reverse split · 30 Jan 2024
- 27-to-26 reverse split · 25 Jan 2017
- 4-for-1 split · 14 Jul 2000
- 2-for-1 split · 16 Jul 1999
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.